Theragnostics Ltd: Developing New Radiotherapies Targeted To PARP
Prostate Cancer Is One Of The Initial Targets For Theragnostics' Technology
Executive Summary
Emerging Company Profile: The transatlantic radiopharmaceuticals start-up Theragnostics Ltd. is developing radiotherapeutics and radiodiagnostics for prostate and other cancers.
You may also be interested in...
AAA Ramps Up Lutathera Launch And Plans Expansion Under Novartis Ownership
Advanced Accelerator Applications is ramping up the launch of the first-in-class peptide receptor radionuclide therapy (PRRT), but Novartis has much broader ambitions for the radiopharmaceutical platform. AAA President Susanne Schaffert talked to Scrip about the growth strategy.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.